SCHEMBL30217876

SCHEMBL30217876

COCCOc1ccc2c(N3CCN(C(=O)OC(C)(C)C)CC3)ccc(C(=O)OC)c2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.41
PTPN11 Q06124 1/20 0.41
ACHE P22303 2/20 0.40
MAP4K4 O95819 1/20 0.39
SLC2A1 P11166 1/20 0.39
RET P07949 1/20 0.39
POLB P06746 1/20 0.39
CKS1B P61024 1/20 0.39
SKP1 P63208 1/20 0.39
SKP2 Q13309 1/20 0.39
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 1/20 0.38
TSHR P16473 1/20 0.38
KMT2A Q03164 1/20 0.38
GPR119 Q8TDV5 3/20 0.38
KIT P10721 2/20 0.38
LMNA P02545 1/20 0.38
FLT3 P36888 1/20 0.38
NR1H2 P55055 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29256966 1.00 BACE1 (0.41) BACE1PTPN11ACHEMAP4K4SLC2A1
SCHEMBL30217840 0.92 CKS1B (0.41) BACE1PTPN11ACHEMAP4K4SLC2A1
SCHEMBL25095896 0.92 CKS1B (0.41) BACE1PTPN11ACHEMAP4K4SLC2A1
SCHEMBL25096826 0.88 BACE1 (0.42) BACE1PTPN11ACHEMAP4K4SLC2A1
SCHEMBL30217688 0.88 BACE1 (0.42) BACE1PTPN11ACHEMAP4K4SLC2A1
SCHEMBL25096370 0.86 BACE1 (0.40) BACE1PTPN11ACHEMAP4K4SLC2A1
SCHEMBL30217836 0.86 BACE1 (0.40) BACE1PTPN11ACHEMAP4K4SLC2A1
SCHEMBL31082782 0.86 WDR5 (0.34) MAP4K4MEN1KMT2AGPR119NR1H2
SCHEMBL25096832 0.83 BACE1 (0.43) BACE1PTPN11ACHEMAP4K4SLC2A1
SCHEMBL30217692 0.83 BACE1 (0.43) BACE1PTPN11ACHEMAP4K4SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240409536-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2024-12-12 US disclosed
EP-4395891-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2024-07-10 EP disclosed
WO-2023034811-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240409536-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 BACE1 668/4885PTPN11 4588/4885ACHE 3477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.